Vanguard CPV.

Country: Irlanda

Lingwa: Ingliż

Sors: HPRA (Health Products Regulatory Authority)

Ingredjent attiv:

Live canine parvovirus strain NL-35-D

Disponibbli minn:

Zoetis Belgium S.A.

Kodiċi ATC:

QI07AD01

INN (Isem Internazzjonali):

Live canine parvovirus strain NL-35-D

Dożaġġ:

.

Għamla farmaċewtika:

Solution for injection

Tip ta 'preskrizzjoni:

POM: Prescription Only Medicine as defined in relevant national legislation

Grupp terapewtiku:

Dogs

Żona terapewtika:

canine parvovirus

Indikazzjonijiet terapewtiċi:

Immunological - Live Vaccine

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2014-09-12

Karatteristiċi tal-prodott

Health Products Regulatory Authority
06 October 2017
CRN000WDG
Page 1 of 5
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Vanguard CPV
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Quantity per 1 ml dose
ACTIVE SUBSTANCE(S):
Live attenuated canine Parvovirus, strain NL-35-D, low passage,
minimum :
10
7.0
CCID
50
*
*Cell culture infectious dose-50
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
The liquid is slightly turbid, reddish in colour.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs from 5 weeks of age.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of dogs to prevent mortality and clinical signs
including
leucopenia and reduce viral shedding caused by canine parvovirus
(types 2a, 2b and
2c).
Onset of immunity occurs by approximately two weeks after the last
dose of the
basic vaccination scheme. Onset of immunity for the canine parvovirus
component
(type 2b) occurs 7 days after a single dose when animals are
vaccinated from 9 weeks
of age.
The duration of immunity is 12 months, after the last dose of the
basic vaccination
scheme based on serology/challenge data.
4.3 CONTRAINDICATIONS
Do not use in unhealthy animals.
Health Products Regulatory Authority
06 October 2017
CRN000WDG
Page 2 of 5
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
The canine parvovirus vaccinal strain may be shed from vaccinated
animals for a
number of days following vaccination. However, due to the low
pathogenicity of this
strain, it is not necessary to keep vaccinated animals seperated from
non-vaccinated
animals.
Due to the presence of maternally derived antibodies, a small
percentage of pups
may fail to mount an adequate immune response to vaccination and may
be at risk
from disease when the local disease challenge is sufficiently high.
The percentage of
puppies that fail to mount an adequate immune response to vaccination
is greater
when the final vaccination is given at 10 weeks of age than